Christine Walsh, MD, MS
Professor, OB-GYN-Gynecologic Oncology

Publications

• Walsh CS, Hacker KE, Secord AA, DeLair DF, McCourt C, Urban R. Molecular testing for endometrial cancer: An SGO clinical practice statement. Gynecol Oncol. 2023 Jan;168:48-55. PMID: 36399812
• Schwartz ZP, Li AJ, Walsh CS, Rimel BJ, Alvarado MM, Lentz SE, Cass I. Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes. Gynecol Oncol. 2023 Apr 6;173:1-7. PMID: 37030072
• John CS, Fong A, Alban R, Gillen J, Moore KM, Walsh CS, Li AJ, Rimel BJ, Amersi F, Cass I. Breast cancer surveillance following ovarian cancer in BRCA mutation carriers. Gynecol Oncol. 2022 Jan;164(1):202-207. PubMed PMID: 34862065
• Walsh CS, Leath CA 3rd, Mayadev J, Randall LM, Urban R. Cervical cancer - times… they are a changing: A report from the Society of Gynecologic Oncology journal club. Gynecol Oncol Rep. 2022 Apr;40:100949. PubMed PMID: 35359489
• Mortlock S, Corona RI, Kho PF, Pharoah P, Seo JH, Freedman ML, Gayther SA, Siedhoff MT, Rogers PAW, Leuchter R, Walsh CS, Cass I, Karlan BY, Rimel BJ, Montgomery GW, Lawrenson K, Kar SP. A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes. Cell Rep Med. 2022 Mar 15;3(3):100542. PubMed PMID: 35492879
• Penn CA, Carballo EV, Walsh CS, Zivanovic O, Kim KH. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy at primary cytoreduction of epithelial ovarian cancer based on residual disease status. Gynecol Oncol Rep. 2022 Jun;41:101009. PubMed PMID: 35652061
• Jernigan A, Farley J, Walsh C. Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer. Gynecol Oncol. 2022 Aug;166(2):207-210. PubMed PMID: 35717268
• Gull N, Jones MR, Peng PC, Coetzee SG, Silva TC, Plummer JT, Reyes ALP, Davis BD, Chen SS, Lawrenson K, Lester J, Walsh C, Rimel BJ, Li AJ, Cass I, Berg Y, Govindavari JB, Rutgers JKL, Berman BP, Karlan BY, Gayther SA. DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancers. J Exp Clin Cancer Res. 2022 Jul 27;41(1):232. PubMed PMID: 35883104
• Walsh CS, Kamrava M, Rogatko A, Kim S, Li A, Cass I, Karlan B, Rimel BJ. Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. PLoS One. 2021;16(6):e0252665. PubMed PMID: 34081738
• Walsh C, Cass I. Poly(ADP-Ribose) Polymerase Inhibitors and Myeloid Neoplasm Risk-Clues to a Mechanistic Connection?. JAMA Oncol. 2021 Dec 1;7(12):1763-1765. PubMed PMID: 34647967